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transfer. Other permutations, such as links with Timbuktu Pro via Internet could also be useful and need to be explored.
The simple and economical methods described here should greatly facilitate interactions between flow cytometry centers. Although our primary interest is the exchange of data used for the immunophenotyping of leukemia, these methods are clearly applicable to all uses of flow cytometry. We believe that these methods would particularly benefit multicenter clinical trials by allowing the transfer of flow cytometric data to a central site for uniform analysis. They would also allow experienced operators to train or closely monitor less experienced operators in conducting analyses, thus improving the accuracy of diagnosis while providing continuing education. Finally, the systematic comparison of the parameter used for disease classification in multiple centers should help the achievement of widely accepted consensus criteria, and the development of automated classification programs. leukemic cells with 11q23 translocations. 2 To address the question of such a genotype-phenotype association in our patient population, we analyzed G-CSF receptor expression and 11q23/MLL genotype in eight ALL patients up to 18 month of age. Patients were selected from the ALL-BFM 90 and ALL-BFM 95 trials of childhood ALL, 3 conducted by the Berlin-Frankfurt-Mü nster (BFM) study group, according to age at diagnosis (р18 month) and based on the availability of a cryopreserved initial bone marrow sample. The percentage of leukemic blasts in the selected initial bone marrow samples ranged from 85 to 98%. Immunophenotyping and definition of phenotypic subgroups were essentially as described before. 4 Surface antigens were considered positive when у20% of leukemia cells expressed the respective surface marker with more than 98% fluorescence intensity. Myeloid antigens tested for co-expression included CD13, CD33, and CD65s. All these analyses were carried out at the time of diagnosis. Flow cytometric analysis of G-CSF receptor expression was performed by use of cryopreserved initial mononuclear bone marrow samples and the mouse monoclonal anti-G-CSF receptor antibody Mab 129 (IgG1). 5 Cytogenetic analyses were carried out at the time of diagnosis using standard techniques. 6 MLL genotyping was performed as described before using genomic DNA isolated from cryopreserved initial leukemic bone marrow samples. 7 Patient characteristics and results are summarized in Table 1 . In flow cytometric analyses, we detected G-CSF receptor expression in Table 1 ). In none of these patients' leukemia cells did we observe any G-CSF receptor expression. Thus, in contrast to the results of Inukai et al,
2
G-CSF-receptor expression and 11q23/MLL rearrangements were not inextricably linked in our patient population. Since our patients expressing the G-CSF receptor were treated within the intermediate risk group of the ALL-BFM 90 study, they did not receive recombinant human G-CSF during the treatment period. Therefore, no conclusions on the course of disease under exposure to G-CSF can be drawn from our results. Although, in a randomized phase III study on the efficacy of G-CSF in children with high-risk ALL from the ALL-BFM 90 trial, no effect of G-CSF treatment on prognosis was observed. 8 However, the expression of G-CSF receptors in two of eight analyzed patients seemed surprisingly high to us. This, together with the notion of an approximate prevalence of MLL gene rearrangements in probably 50% of infant acute lymphoblastic leukemias, 9 makes it likely that coincidence of G-CSF receptor expression and 11q23/MLL rearrangement is not an unfrequent event in this age group. Further studies are needed to evaluate this important clinical issue in the future. 
